For research and educational purposes only. Not medical advice.
Zaleplon Reference
Educational, not medical advice reference for Zaleplon: Sleep; regulatory status, evidence posture, source review, and schedule notes. Also known as Sonata,…
Reference summary
Dundar 2004 Health Technol Assess systematic review covers zaleplon alongside zolpidem, eszopiclone, and zopiclone for short-term insomnia. Zaleplon's distinctive feature is the rapid elimination - the short half-life makes mid-sleep dosing viable when at least 4 hours of sleep time remain, which is not appropriate for the longer-acting Z-drugs.
Regulatory and posture
- Categories
- Sleep
- Aliases
- Sonata, Non-benzodiazepine GABA-A agonist (small molecule, not a peptide)
- Evidence posture
- human
- Regulatory status
- FDA-approved as Sonata (1999) for the short-term treatment of insomnia. Schedule IV controlled substance. The shortest-half-life Z-drug (~1 hour), positioning it for sleep-onset and middle-of-the-night use.
- Content review status
- label verified